Artificial Intelligence

With a key presentation looming, Star Therapeutics aims to showcase its universal hemostatic therapy, VGA039, for von Willebrand disease.

Routeware appoints proven tech leaders Jeremy Collins and Ray Greer to drive its next growth phase, focusing on platform modernization and market leadership.

With blockbuster sales from VYJUVEK, Krystal Biotech heads to J.P. Morgan with investors eager for news on its global growth and ambitious pipeline.

A tiny implant stimulating the vagus nerve offers new hope for severe RA. A landmark study now validates this bioelectric therapy for patients out of options.

Off The Hook's new luxury division leverages AI and an integrated model to secure ~$100M in listings and close 22 deals in its explosive first quarter.

A new integration brings Ceres AI's insights directly into the John Deere Operations Center, tackling data fragmentation for growers and insurers alike.

A new therapy claims to reverse cellular aging to cure disease, but its patient-funded trial model sparks a debate on equity and medical ethics.

Amid a capacity crisis, a new model blending AI with human oversight gains traction, promising efficiency without sacrificing the crucial element of patient care.

China's ETF market had a record 2025, fueled by AI breakthroughs and state support. A look at the boom, the leaders, and the risks ahead.

Circle Pharma will unveil its pipeline of novel oral macrocycle drugs targeting elusive cancer drivers at the influential J.P. Morgan Healthcare Conference.

With record Q3 earnings and strong analyst ratings, Red Violet is set to present its identity intelligence growth strategy at the prestigious Needham conference.

AMC Robotics establishes a new manufacturing hub in Ho Chi Minh City, a strategic move to scale its Kyro robot and join the global tech shift to Vietnam.

With promising 3-year vision data and a manufacturing breakthrough, Lineage is pioneering 'off-the-shelf' cell therapies for blindness, diabetes, and more.

With pivotal Phase 2 data for its non-invasive skin cancer patch due in Q1, Medicus Pharma is advancing a diverse pipeline fueled by AI and strategic acquisitions.

A landmark $1.2M order for its advanced LineaDNA validates the firm's biotech arm, but can scientific success balance its new, volatile crypto strategy?

Formerly Cybin, Helus Pharma's Nasdaq launch marks a pivotal shift towards commercializing its breakthrough depression and anxiety drug pipeline.

A new 10,000-sample 'skin library' collected by painless stickers aims to slash drug development time and costs for biopharmaceutical partners.

Acorn Energy partners with AIO Systems to bring AI-driven monitoring to cell towers and data centers, targeting a market projected to exceed $13 billion.

Gyre Therapeutics secures a pivotal conditional approval pathway in China for its novel liver fibrosis drug, offering hope for millions of hepatitis B patients.

A new partnership aims to unlock the potential of a next-gen obesity drug by pairing it with advanced delivery tech to overcome historical hurdles.